ClinicalTrials.gg
CompletedNCT00002391Updated Jun 24, 2005

The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs

A Phase 3 interventional study of Abacavir sulfate and Lamivudine in HIV Infections, sponsored by Glaxo Wellcome. Completed at 30 sites in United States. Open to participants aged 3 Months to 12 Years. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Ages
3 Months to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.

Phase 3
50 of 132
2 open now
Registered
1st of 132
by date
Lead sponsor
12 of 132
Glaxo Wellcome

Among the 132 studies testing lamivudine in HIV Infections, this one is one of 50 in phase 3, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 3 Months to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing lamivudine in HIV Infections, or all of them as a file.
02

Study summary

To compare the safety, tolerance, durability of the viral load response and the antiviral activity of the 1592U89/zidovudine(ZDV)/lamivudine (3TC) regimen vs. ZDV/3TC regimen. To determine the clinical efficacy of the two regimens as measured survival, disease progression, weight growth velocity, and neuropsychological or neurological changes. To assess the development of viral resistance and relative pharmacokinetics associated with each regimen.

Read the detailed description

Patients are randomized to receive blinded treatment with ZDV/3TC alone or in combination with 1592U89, orally for 16 weeks. If after the 16-week period certain criteria are met, patients may have the option to switch to open-label treatment for the remainder of the study period.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • Drug Therapy, Combination
  • Zidovudine
  • Lamivudine
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • Viral Load
  • Child Development
  • abacavir
04

Who can participate

Ages eligible
3 Months to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Concurrent Medication:

Allowed:

  • Intravenous immunoglobulin G, erythropoietin, G-CSF and GM-CSF.
  • Opportunistic infection prophylaxis.

Patients must have:

  • -1 infection documented by:

\< 18 months of age:

  • one positive viral test culture and one other positive viral test (culture, PCR, p24 antigen, or Immune Complex Dissociation p24 antigen) on two different specimens.

>= 18 months of age:

  • two positive viral tests as stated above, one or both of which may be determined by a federally documented ELISA and confirmed by Western blot or Indirect Fluorescent Antibody test.
  • Any of the CDC Categories:
  • 1, 2, 3, and N, A, B, and C of the 1994 Revised Classification System for HIV Infection in Children Less than 13 Years of Age.
  • >= 15% within 14 days prior to study drug administration.
  • No active or ongoing AIDS-defining opportunistic infection that precludes absorption of study drug or observation of a study parameter.
  • Signed, from parent or legal guardian for patients under 18 years of age.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Serious bacterial infection that precludes absorption of study drug or observation of a study parameter.
  • Documented to a nucleoside analog.
  • Co-enrollment in certain opportunistic infection protocols is not exclusionary if approval is obtained.
  • .
  • Life-threatening infection or other chronic disease that may compromise patient safety.
  • Grade 3/4 clinical or laboratory toxicity or current grade 2 or higher pancreatic amylase or lipase toxicity as defined by the ACTG Toxicity Tables within 14 days prior to study entry.

Concurrent Medication:

Excluded:

  • Other anti- therapy.
  • Probenecid.
  • Biologic response modifier (unless listed under included concurrent medication) and megestrol acetate.
  • Human growth hormone.
  • Immunomodulators and cytotoxic chemotherapeutic agents.
  • Systemic > 14 days without approval.
  • agents.

Concurrent Treatment:

Excluded:

Radiation therapy.

Patients with the following prior conditions are excluded:

  • History of pancreatitis or hepatitis within the past 6 months.
  • Participation in a vaccine trial.

Prior Medication:

Excluded:

  • Protease inhibitor therapy within 2 weeks prior to randomization.
  • Interleukins or interferons within 30 days prior to study drug administration.
  • Investigational drugs within 14 days prior to randomization.
  • HIV vaccine dose within past 30 days.

Required:

> 12 weeks prior antiretroviral therapy and unchanged therapy 12 weeks prior to screening.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Intervention model
Parallel assignment

Interventions

06

Study locations

30 sites
  • Univ Alabama - Birmingham / Dept of Pediatrics / UAB Station
    Birmingham, Alabama 35294, United States
  • Children's Hosp Los Angeles
    Los Angeles, California 90027, United States
  • Los Angeles County - USC Med Ctr
    Los Angeles, California 90033, United States
  • Children's Diagnostic Treatment Ctr
    Fort Lauderdale, Florida 33301, United States
  • Univ of Florida - Gainesville / Infectious Dis & Immun
    Gainesville, Florida 326100296, United States
  • Univ of Miami / Fox Cancer Research Ctr
    Miami, Florida 33136, United States
  • Arnold Palmer Hosp for Women and Children
    Orlando, Florida 32806, United States
  • Pediatric Special Immunology Clinic / HRS / PBC PHU
    Riviera Beach, Florida 33404, United States
  • Univ of South Florida All Children's Hosp
    Saint Petersburg, Florida 33701, United States
  • Dr Patricia Emmanuel
    Tampa, Florida 33606, United States
  • Mt Sinai Hosp Med Ctr / Dept of Pediatrics
    Chicago, Illinois 60608, United States
  • Tulane Univ Med School
    New Orleans, Louisiana 70112, United States
  • Univ of Minnesota Med School
    Minneapolis, Minnesota 55455, United States
  • UMDNJ / Division of Allergy Immunology & Infectious Diseases
    Newark, New Jersey 07103, United States
  • Bronx Lebanon Hosp Ctr / Dept of Pediatrics
    Bronx, New York 10457, United States
  • PACT Program
    Buffalo, New York 14222, United States
  • North Shore Univ Hosp / Pediatric Immunology
    Great Neck, New York 11021, United States
  • Schneider Children's Hosp
    New Hyde Park, New York 11040, United States
  • New York Hosp - Cornell / Program for Children with AIDS
    New York, New York 10021, United States
  • St Luke's - Roosevelt Hosp Ctr
    New York, New York 10025, United States
  • SUNY Health Ctr at Stony Brook / Pediatric Infectious Dis
    Stony Brook, New York 117948111, United States
  • SUNY Health Sciences Ctr at Syracuse / Dept of Pediatrics
    Syracuse, New York 13210, United States
  • Univ of North Carolina / Pediatric Infectious Diseases
    Chapel Hill, North Carolina 27514, United States
  • Duke Univ Med Ctr / Pediatrics Dept / Infec Dis
    Durham, North Carolina 27710, United States
  • The Children's Med Ctr / Division of Infectious Dis
    Dayton, Ohio 454041815, United States
  • Med Univ of South Carolina
    Charleston, South Carolina 294253312, United States
  • Children's Med Ctr of Dallas / ARMS Clinic
    Dallas, Texas 75235, United States
  • Cook's Ft Worth Children Med Ctr / Pediatric Inf Dis
    Fort Worth, Texas 76104, United States
  • Univ of Texas Health Sciences Ctr
    San Antonio, Texas 78284, United States
  • Eastern VA Med Sch / Children's Hosp of the King's Daughters
    Norfolk, Virginia 23507, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002391
Lead sponsor
Glaxo Wellcome
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 1998. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lamivudine · Zidovudine

Start the discussion